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H3K18 acetylationMithramycin (MTR) is a clinically approved DNA-binding antitumor antibiotic currently in Phase 2
clinical trials at National Institutes of Health for treatment of osteosarcoma. In view of the resur-
gence in the studies of this generic antibiotic as a human medicine, we have examined the binding
properties of MTR with the integral component of chromatin – histone proteins – as a part of our
broad objective to classify DNA-binding molecules in terms of their ability to bind chromosomal
DNA alone (single binding mode) or both histones and chromosomal DNA (dual binding mode).
The present report shows that besides DNA, MTR also binds to core histones present in chromatin
and thus possesses the property of dual binding in the chromatin context. In contrast to the
MTR–DNA interaction, association of MTR with histones does not require obligatory presence of
bivalent metal ion like Mg2+. As a consequence of its ability to interact with core histones, MTR
inhibits histone H3 acetylation at lysine 18, an important signature of active chromatin, in vitro
and ex vivo. Reanalysis of microarray data of Ewing sarcoma cell lines shows that upon MTR treat-
ment there is a signiﬁcant down regulation of genes, possibly implicating a repression of H3K18Ac-
enriched genes apart from DNA-binding transcription factors. Association of MTR with core histones
and its ability to alter post-translational modiﬁcation of histone H3 clearly indicates an additional
mode of action of this anticancer drug that could be implicated in novel therapeutic strategies.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mithramycin, MTR (Fig. 1) is a DNA-binding antitumor antibi-
otic of the aureolic acid group isolated from soil borne bacteria likeStreptomyces plicatus [1]. At physiological pH, it exists in anionic
form (pKa = 5.0). It inhibits tumor cell growth without affecting
normal cells [2] via inhibition of Sp1 gene. This is attributed to
the ability of MTR to cross the nuclear membrane, bind to GC rich
DNA sequences and block the Sp1 transcription factor from its
binding sites on the promoters of oncogenes such as Myc to inhibit
their expression [3,4]. Its neuroprotective ability was tested in vitro
and in vivo employing different model systems [5–9]. The major
hurdle for drugs to be used in brain targeting is their ability to
cross the blood–brain barrier which MTR can achieve [6]. It was
reported to improve altered nucleosome homeostasis in HD mice,
normalizing the chromatin modiﬁcation pattern [10]. One of these
studies showed that it has the ability to rebalance epigenetic his-
tone modiﬁcations like acetylation and methylation [10] and has
been used in preclinical trials in Huntington’s disease (HD). MTR
is currently in Phase 2 clinical trial at NIH Clinical Center for treat-
ment of osteosarcoma where it presumably functions via inhibition
Fig. 1. Chemical structure of mithramycin (MTR).
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treatment of various neoplastic diseases like chronic myelogenous
leukemia, testicular carcinoma, pancreatic cancer and prostate
cancer [12–19]. Anionic form of MTR has the ability to bind
bivalent cations and form high-afﬁnity antibiotic–metal ion com-
plexes (1:1 and 1:2 stoichiometry in terms of metal:antibiotic),
which bind to the chromosomal DNA in GC selective manner via
the minor groove at and above physiological pH [20,21]. Thus
MTR–metal complex acts as the substrate for DNA binding [21–
25]. Its antitumor activity is ascribed to its GC speciﬁc recognition
that permits MTR to bind to numerous promoter regions, thereby
regulating the expression of downstream genes. It effectively
inhibits the expression of proto-oncogenes like c-myc, c-Ha-ras
and c-myb [26–29].
Current studies from our laboratory have shown the histone
binding potential of DNA binders and their ability to alter histone
post-translational modiﬁcations (PTMs) [30,31]. Hence it is likely,
that MTR may have additional interacting partners in chromatin.
Taking a cue from the above studies, we have examined the
binding properties of MTR with other prospective cellular targets
namely histone proteins with an objective to classify small DNA
binding molecules in terms of their ability to bind chromosomal
DNA alone (single binding mode) or both histones and chromo-
somal DNA (dual binding mode) [30–33].
The current study reports the association of MTR with core
histones and its functional consequence. The interactions are
enthalpy driven with apparent dissociation constants of micromo-
lar order. The noteworthy feature of this interaction is that unlike
MTR–DNA interaction, bivalent metal ion such as Mg2+ is not a
requirement for the association of MTR with core histones. We
have picked up few histone modiﬁcations related to transcription
regulation and have found that MTR is a potent inhibitor of K18
acetylation mark of histone H3, both in vitro and ex vivo. Taken
together, our results indicate that MTR exhibits a dual binding
mode to both DNA and core histones and can speciﬁcally modulate
epigenetic signature implicated in transcription [6,34]. Thus this
study opens up a new aspect of the mode of action of the antibiotic,
MTR.
2. Materials and methods
2.1. Materials
Chemicals were purchased from Sigma Chemical Company,
USA, unless otherwise speciﬁed. Recombinant histones H10, H2A,
H2B, H3.3, H4, H2A–H2B dimer and H3.1–H4 tetramer were from
New England Biolabs. Anti-acetyl-Histone H3 (Lys18 and Lys 27)
antibodies were purchased from Abcam and anti-acetyl-Histone
H3 (Lys 9) antibody was from Millipore. The secondary anti-rabbit
antibody was from Abcam. Chemiluminescent substrates were
from Thermo Scientiﬁc (SuperSignal West Pico Substrate) and the
developer and ﬁxer solutions were from Kodak. Histone
acetyltransferase CBP and GCN5 were from Enzo Life Sciences.
The commercial histones were dialyzed extensively against
10 mM Tris–HCl, pH 7.0 containing 150 mM NaCl prior to
experiments.2.2. Methods
2.2.1. Preparation of MTR solution
Stock solution was prepared in Milli Q water and the concentra-
tion was determined spectrophotometrically using the molar
extinction coefﬁcient (e = 10,000 M1 cm1) [35] at 400 nm. The
ratio of absorbance of MTR at 400–440 nm was checked to be
above 3.3 to rule out any bivalent metal contamination.
2.2.2. Preparation of chromatin samples
Chromatin and chromatosomes were isolated from liver of male
albino Sprague–Dawley rats following standard protocol [36].
Internationally recognized guidelines were followed for all experi-
ments using rat. The experiments were performed with the
approval for ethical clearance from Institutional Animal Ethics
Committee, IAEC (Approval No.: IAEC/BI/09/2012), Bose Institute,
Kolkata. In brief, rat liver nuclei were isolated [31,36,37] and
chromatin was prepared by partial digestion with micrococcal
nuclease. Long fragments and chromatosomes were separately
collected by centrifugation through a 5–25% linear sucrose density
gradient. All samples, prior to experiment were dialyzed exten-
sively against 10 mM Tris–HCl, pH 7.0 containing 15 mM NaCl
and mononucleotide concentrations of the samples were
determined spectrophotometrically using the molar extinction
coefﬁcient (e260) of 6600 M1 cm1.
Core octamer was prepared from chicken erythrocytes using the
method described by Peterson and Hansen [38]. Prior to experi-
ments, the core octamer was dialyzed against 10 mM Tris–HCl,
pH 7.0, 2 M NaCl. Concentration of core octamer was determined
using the molar extinction coefﬁcient (e230) of 507,233 M1 cm1.
2.2.3. Steady state ﬂuorescence measurements
The ﬂuorescence emission spectra of MTR were monitored in
presence of recombinant histones, core octamer, H2A–H2B dimer,
H3–H4 tetramer, chromatin/chromatosome and N-terminal
histone peptides where MTR/protein ratio was gradually increased.
The samples were excited at 470 nm in order to avoid photodegra-
dation of MTR [25]. The excitation and emission slit widths were
kept at 10 nm and the scan speed was 200 nm/min. An incubation
time of 3 min was maintained before each reading. The measure-
ments were performed in a Perkin Elmer LS 55 Luminescence
Spectrometer at 25 C.
2.2.4. Isothermal titration calorimetry
MTR was titrated against histones H2A, H2B, H3.3 and H4 in a
Microcal ITC 200 microcalorimeter at 25 C with a constant stirring
speed of 300 rpm. Control experiment was performed for each
system to subtract the background heat of dilution. The resulting
thermogram was ﬁtted employing one set of binding sites model
of Levenberg–Marquardt nonlinear least squares curve ﬁtting
algorithm, inbuilt in the MicroCal LLC software.
2.2.5. Circular dichroism study
The circular dichroism measurements were performed in a
Spectropolarimeter from Bio Logic Science Instruments, France
and data were analyzed with inbuilt Bio-Kine 32 V4.49-1 software.
The measurements were performed at 25 C. The molar ellipticity
was plotted against the wavelength. Acquisition duration was ﬁxed
at 2 s and the required wavelength range was scanned at 0.5 nm
intervals. Each spectrum was an average of 4 accumulations and
the corrected spectra were obtained by subtraction of the
appropriate control.
2.2.6. Electron microscopy
Chromatin was extensively dialyzed against HEGN buffer
(10 mMHepes, pH 7.5; 0.25 mM EDTA; 10% glycerol; 15 mMNaCl).
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incubated for 3 h at 25 C in a water bath. Treated and untreated
samples were processed for electron microscopy study as detailed
in the Supplemental methods section.
2.2.7. Dynamic light scattering
Dynamic light scattering was used as a tool to examine MTR-
induced alteration of chromatin structure, if any. The parameter
monitored was the hydrodynamic diameter of untreated and
MTR-treated chromatin. The detailed procedure is provided in
the Supplementary section.
2.2.8. Histone acetyltransferase (HAT) assay
Standard HAT assay protocol was followed as reported previ-
ously [39]. 2 lg of recombinant histone H3 was incubated in HAT
assay buffer containing 50 mM Tris–HCl, pH 8.0, 10% (v/v) glycerol,
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl ﬂuoride, 0.1 mM
EDTA, pH 8.0, 0.1 mM sodium butyrate at 30 C for 10 min in the
presence and absence of MTR followed by addition of 1 lL of
acetyl-CoA and further incubated for another 10 min at 30 C.
The ﬁnal reaction volume was 30 lL. The acetylation reaction
was terminated by chilling. Histone was precipitated by trichloro-
acetic acid (TCA) and analyzed on a 15% SDS page followed byWes-
tern blot analysis. The acetylation marks probed were H3K18
(dilution 1:5000 in 3% skim milk prepared in TBST), H3K9 (dilution
1:10,000) and H3K27 (dilution 1:1000). Signals were generated
using chemiluminescent substrates in a dark room on X-ray ﬁlms
providing very short exposures of 2 s and the blots were devel-
oped using developer and ﬁxer solutions.
2.2.9. Flow cytometry analysis
HeLa cells (untreated or treated with 10 lM MTR for 9 h) were
subjected to ﬂow cytometry analysis as described in the Supple-
mental methods section.
2.2.10. Cell viability assay (MTT assay)
MTT assay was performed following standard protocol [40] to
test the cell viability upon MTR treatment. The method is detailed
in the Supplementary section.
2.2.11. Cell culture and MTR treatment
HeLa cells were maintained in Dulbecco’s modiﬁed Eagle’s med-
ium (Gibco) supplemented with 10% fetal bovine serum (Gibco)
and penstrep (10 lL/mL of medium, Gibco) at 37 C in 5% (v/v) CO2.
For MTR treatment, HeLa cells were plated in 90 mm dishes
(Nunc) at a density of 1.2 million cells per dish. The cells were
treated with 10 lM MTR for 9 h. After treatment, the cells were
observed under light microscope and processed for immunoblot
analysis.
2.2.12. Immunoblot analysis
HeLa cells were harvested after rinsing with 1 PBS and whole
cell extracts were made in Laemmli buffer (4% SDS, 20% Glycerol,
120 mM Tris, pH 6.8) as per standard protocol [41]. Total protein
extracts were boiled in 5 SDS buffer and analyzed in a 15% gel
followed by Western blotting. The blot was probed with
H3K18Ac primary antibody (dilution 1:10,000).
2.2.13. Confocal microscopy
For immunoﬂuorescence staining, HeLa cells were grown in
35 mm tissue culture dish (Nunc) with a cover slip at a density
of 0.3 million cells per dish. They were treated with different
concentrations (0.1–10 lM) of MTR for 9 h. The cells were rinsed
with 1 PBS and then ﬁxed with 4% PBS at room temperature for
10 min. The cells were subsequently permeabilized in 1% Triton
X-100 for 10 min at room temperature. Cells were blocked with3% BSA in PBS, incubated with anti-rabbit-H3K18Ac antibody
(Active Motif) at a dilution of 1:1000, followed by Alexa 568 conju-
gated anti-rabbit–antiserum at a dilution of 1:1000 for 1hour each
at room temperature. The cover slips were mounted onto a glass
slide with a commercial mounting medium (Invitrogen). The slides
were visualized in Andor Spinning Disk Confocal Microscope and
multiple images were taken at different ﬁelds. Higher magniﬁca-
tion images were taken in a super resolution microscopy N-SIM
(Nikon) equipped with Nikon Imaging Software (NIS). Detailed sta-
tistical analysis was done to quantify the extent of repression of
H3K18 acetylation upon increasing concentration of MTR treat-
ment, using Image J software.
2.2.14. Gene expression analysis upon MTR treatment
In order to understand the basal level effect of MTR on gene
expression, we used the publically available microarray data of
MTR treated sarcoma cell line from NCBI GEO with series accession
number GSE25127. The data consist of two cell lines TC71 and
TC32, which were treated with or without MTR and differential
gene expression analysis was performed in 12 arrays (three biolog-
ical replicates per cell line/treatment). The detailed procedure for
data analysis is described in the Supplementary section.
3. Results
3.1. Evidence for physical association of MTR with core histones and
the associated energetics
Interactions of MTR:M2+ complexes (M2+: bivalent metal ion
such as Mg2+) with DNA or chromatin have been well-character-
ized [20–22,24,25,42]. Since core histones are integral components
of chromatin, MTR could have a potential histone interacting abil-
ity in the cellular context. However, there is no report yet on the
interaction of anionic MTR with histone(s) at or near physiological
pH. We have characterized here the association of MTR with his-
tones by means of steady state ﬂuorescence and circular dichroism
spectroscopy. Histone concentration dependent decrease in ﬂuo-
rescence emission intensity of MTR upon addition of individual
core histone proteins suggests their complex formation. The ﬂuo-
rescence spectrum of MTR (kex = 470 nm) [25], is progressively
quenched in presence of increasing concentrations of histone(s)
H2A, H2B, H3 and H4 (Fig. 2A and Fig. S1). The plot of emission
intensity at peak (540 nm) against histone concentration is
characteristic of a linear binding isotherm originating from the
association between the histone(s) and MTR. Curve ﬁtting analysis
[24,42,43] shows that MTR binds to histones with micromolar dis-
sociation constant (Table 1). Conformational alteration of MTR in
presence of core histones was probed by CD spectroscopy. The
molar ellipticity of MTR decreased in presence of core histones
supporting the complex formation (Fig. 2B for histone H3 and
Fig. S2 for the rest). The core histones are assembled under
in vivo conditions as an octamer [44]. At physiological ionic
strength (150 mM NaCl) histone octamer stripped off DNA exists
as dimer–tetramer equilibrium [45]. Under in vitro conditions such
octamer is formed at high salt concentration of 2 M NaCl [45]. We,
therefore, studied the association of MTRwith hierarchical levels of
octamer assembly, viz. individual core histones (Fig. 2 and Fig. S1),
H2A–H2B dimer, H3–H4 tetramer (Fig. S3) and octamer (Fig. 3A) by
means of ﬂuorescence to check if there is any difference in the nat-
ure of interaction. In case of octamer, the band around 550 nm in
the emission spectrum of free MTR gives way to a red-shifted
new band around 600 nm. The equilibrium between free and oct-
amer bound MTR was indicated from the binding isotherm
obtained from a plot of the emission intensity of MTR at 600 nm
against the input concentration of the octamer. The signiﬁcant
red shift of the emission peak of MTR can be ascribed to alteration
Fig. 2. (A) Binding isotherm for the interaction of MTR with histone H3 in 10 mM Tris–HCl, pH 7.0 containing 150 mM NaCl at 25 C obtained from steady state ﬂuorescence
spectroscopy. Inset shows the emission spectra of 2 lM MTR in absence (black) and presence of increasing concentrations (0.5 lM, red; 1 lM, blue; 2 lM, green) of human
recombinant histone H3. kex = 470 nm. (B) Circular dichroism spectra of 8 lM MTR in 10 mM Tris–HCl, pH 7.0 containing 150 mM NaCl at 25 C in absence (black) and
presence of 1 lM (red) and 4 lM (green) histone H3 in the visible range. (C) ITC proﬁle for the association of MTR with histone H3 at 25 C in 10 mM Tris–HCl, pH 7.0
containing 150 mM NaCl. The lower panel contains the background heat subtracted ﬁtted isotherm. Emission spectra of 2 lM MTR in 10 mM Tris–HCl, pH 7.0 containing
150 mM NaCl at 25 C in absence (black) and in presence of (2 lM, red; 4 lM, green; 9 lM, blue) N-terminal tail peptide H3 (residues 1–21). kex = 470 nm. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Dissociation constants of MTR–histone interactions at 25 C as obtained from
spectroﬂuorimetric analysis.
Histones Kd (lM)
H2A 0.96 ± 0.02
H2B 1.7 ± 0.05
H3.3 0.66 ± 0.02
H4 1.25 ± 0.05
H2A–H2B dimer 0.78 ± 0.03
H3.1–H4 tetramer 0.77 ± 0.03
Fig. 3. (A) Interaction of MTR with core octamer in 10 mM Tris–HCl, pH 7.0 containing 2
Inset: Emission spectra of MTR (2 lM) in absence (black) and in presence (red) of 3.3 lM
10 mM Tris–HCl, pH 7.0 containing 2 M NaCl at 25 C in absence (black) and in presence o
ﬁgure legend, the reader is referred to the web version of this article.)
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which is possibly caged into the assembled octamer. The contribu-
tion of other parameters such as electrostatic interaction of the
anionic MTR with positively charged amino acid in the N-terminal
tails in the histone also appears to be a plausible factor. The
dissociation constant value of 0.60 ± 0.01 lM is relatively lower
than the corresponding values for the individual histone(s) imply-
ing stronger association when the core histones form octamer. The
concentration dependent variation in molar ellipticity of core his-
tone octamer with gradual addition of MTR (Fig. 3B) is another evi-
dence for MTR-octamer association. The possibility of interactionM NaCl at 25 C: Binding isotherm obtained using non-linear curve ﬁtting analysis.
core octamer. kex = 470 nm. (B) Near UV CD spectra of 3.3 lM histone octamer in
f increasing MTR concentrations. (For interpretation of the references to color in this
Table 2
Thermodynamic parameters of MTR–histone interactions in 10 mM Tris–HCl, pH 7.0
containing 150 mM NaCl as obtained by ITC at 25 C.
Histone Kd (lM) DH (kcal mol1) DS (e.u.) DG (kcal mol1)
H2A 0.05 ± 0.01 14.8 ± 0.7 16.2 9.97
H2B 1.4 ± 0.05 14.1 ± 1.2 20.4 8.02
H3.3 0.05 ± 0.01 24.3 ± 0.96 49.0 9.70
H4 0.051 ± 0.03 24.3 ± 0.65 48.1 9.99
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emission intensity of MTR decreases upon progressive addition of
H3 tail peptide (residues 1–21, Fig. 2D). Fig. S4 shows the percent-
age change in ﬂuorescence intensity of MTR at the emission
maximum as a function of input concentration of the N-terminal
tail peptides (of histone H2A, H2B, H3 and H4). The results suggest
a preferential interaction between MTR and the N-terminal tail (1–
21 residues) of H3.
Association of MTR with core histone(s) and the energetics of
the interactions were quantitated by means of ITC. Representative
thermograms for the titration of MTR with histones, H2A, H2B, H3,
and H4 are shown in Fig. 2C and Fig. S5. The thermodynamic
parameters obtained by ITC are summarized in Table 2. The associ-
ation with histone(s) has also been carried out at high salt concen-
tration to eliminate the possibility of non-speciﬁc association
(Fig. S6 and Table S2). The interactions are enthalpy driven and
enthalpy–entropy compensation accounts for the overall free
energy change for the reactions. In order to investigate the ability
of MTR to interact with linker histones (if any), ITC and ﬂuores-
cence measurements were performed. No signiﬁcant interaction
between MTR and linker histone H1 was scored by either of the
two methods (Figs. S1D and S5D). The interaction of MTR with core
histones might induce structural alterations like compaction/
decompaction of chromatin as caused by other DNA binding small
molecules [30,37]. The possibility was examined using DLS andFig. 4. Emission spectra of 20 lM MTR in 10 mM Tris–HCl, pH 7.0 containing 15 m
chromatosome (D). kex = 470 nm. Panels (B) and (E) show corresponding binding isothe
15 lM MTR monitored at 25 C in absence (black) and presence of chromatin (C) and ch
chromatin/chromatosome respectively. (For interpretation of the references to color in tEM. The hydrodynamic diameter of chromatin was monitored in
absence and presence of different concentrations of MTR by DLS.
The Zav diameter of chromatin was found to be 132.8 nm in
absence of MTR and the same was noted to be 131.8 nm at a
ligand: DNA base ratio of 0.25 (Fig. S7A). EM images of untreated
and MTR-treated chromatin (Fig. S7B) suggest that MTR causes
no signiﬁcant alteration of chromatin structure. The chromatin
network is retained in presence of MTR and no change in the com-
pactness of chromatin was observed upon MTR treatment. These
data rule out the possibility of H1 eviction by MTR.
3.2. Metal-independent binding of MTR to chromatin
It was previously proposed that MTR binds to chromatin only in
presence of bivalent metal ions like Mg2+ via minor groove of DNA
[42]. Here we have shown that the interaction of MTR with chro-
matin occurs even in absence of Mg2+. In contrast to the interaction
with free histones, the ﬂuorescence intensity of MTR at 540 nm
increases (Fig. 4, panels A and D) with addition of aliquots of
chromatin/chromatosome and eventually reaches a plateau. The
dissociation constant is in the micromolar range (Table S1). Nota-
ble feature is that the association in all cases described above is
stronger than that was reported in case of chromatin with the
MTR:Mg2+ complexes [21,42]. Chiro-optical properties of MTR in
the visible region were monitored to examine its association with
chromatosome and chromatin. The CD spectral behavior of MTR in
presence of chromatin (Fig. 4C) and chromatosome (Fig. 4F) is
similar to that of interaction of MTR with individual histones
corroborating the proposal that MTR interacts with histones in
chromatin/chromatosome.
3.3. Role of MTR as an epigenetic modulator
The cell modulates nucleosome mobility and turnover via
chemical modiﬁcations of histones. We have demonstrated thatM NaCl at 25 C in presence of increasing concentrations of chromatin (A) and
rms for MTR–chromatin/chromatosome interactions. Circular dichroism spectra of
romatosome (F). Red curves represent 45 lM and blue curves represent 120 lM of
his ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. In vitro HAT assay to examine alteration of H3K18 acetylation (A), H3K9 acetylation (B) and H3K27 acetylation (C) by MTR in recombinant histone H3. (D) Modulation
of H3K18 acetylation, ex vivo, probed by Western blot analysis of MTR-treated HeLa cells. Extent of MTR-induced repression of H3K18Ac has been quantiﬁed by Image J
software. (E) Inhibition of H3K18 acetylation in HeLa cells by MTR monitored by confocal microscopy. The scale bar is 10 lm.
Fig. 6. Unsupervised hierarchical clustering of differentially expressed genes (A)
using Pearson uncentered algorithm with average distance matrix shows distinct
patterns of up and down regulated genes upon treatment in comparison to
untreated samples. Venn diagram representation (B) of up and down regulated
genes between two cell lines indicates less number of genes that are commonly
regulated by MTR.
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tion between MTR and histone H3 tail (1–21 amino acids). N-ter-
minal tails of the core histones undergo PTMs and impact
chromatin structure and function. Taking a cue from literature,
where histone interacting small molecules are found to modulate
its PTMs (such as histone acetylation) [30,31,46] we went on to
check whether MTR can alter histone acetylation. We have picked
up few commonly studied N-terminal acetylation marks of his-
tones H3 and H4. H3K18Ac, an important transcription activation
mark, is altered in presence of MTR both in vitro and ex vivo. In vitro
HAT assay using CBP HAT domain, showed that MTR inhibits
H3K18Ac (Fig. 5A). Acetylation levels at two other acetylation sites
H3K9Ac (by GCN5) and H3K27Ac (by CBP) [47] were not altered in
presence of MTR (Fig. 5B and C). Neither did we notice any change
in the acetylation levels of H4K5Ac and H4K8Ac (by CBP) (Fig. S8).
Since H3K18Ac was altered in vitro, we further investigated the
modulation of H3K18Ac mark in cellular context. It was found that
MTR inhibits H3K18Ac in a dose dependent and time dependent
manner in HeLa cells by immunoblot analysis (Fig. S9). Reduction
in acetylation level was prominent upon 10 lM MTR treatment
for 9 h (Fig. 5D, compare lanes 1 and 2) and almost total inhibition
was found upon 20 lM MTR treatment for 12 h (Fig. 5D, compare
lanes 1 and 3). The variation in H3K18 acetylation status was fur-
ther monitored by confocal microscopy. Titration of different
ligand concentrations in HeLa cells (Fig. S10) showed a prominent
repression (50%) in H3K18Ac level upon treatment with 10 lM
MTR (Fig. 5E).
There could be a possibility that the reduction in H3K18Ac is an
indirect effect through the cytotoxic ability of MTR. In order to
ascertain whether the dosage and time course of MTR treatment
induce apoptosis in HeLa cells, MTT assays were performed. How-
ever, no signiﬁcant cell death was observed even after 15 h of MTR
treatment (Fig. S11D). To reconﬁrm this observation and addition-
ally monitor if MTR can at all inﬂuence cell cycle stages, ﬂow
cytometry analysis was carried out. There was no signiﬁcant
change in the stages of cell cycle upon MTR treatment (Fig. S11A).Literature report shows that SGR, a histone interacting small
molecule capable of modulating histone PTMs can affect global
gene expression [30]. Since MTR binds to core histones and alters
an important epigenetic signature in HeLa cells, we were inter-
ested to do a gene expression analysis as a sequel to the ligand
treatment. From available literature data [48] we have seen that
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(TC32 and TC71). Further, a subset of genes that were differentially
expressed also harbored H3K18Ac. These two separate observa-
tions prompted us to make a reanalysis of microarray data (with
statistical signiﬁcance) and also compare the H3K18Ac enrich-
ments in the gene sets which were differentially expressed. We
wanted to check whether MTR exhibits a basal level activity
irrespective of the cell lines. In our reanalysis we observed gen-
ome-wide repression of gene expression upon treatment with
MTR in TC32 (870 genes were down regulated and 288 genes were
up regulated) and TC71 (532 genes were down regulated and 115
genes were up regulated) cell lines. Unsupervised hierarchical clus-
tering (Fig. 6) showed high degree of similarity in differential
expression in both the cell lines. We have also generated Biological
Analysis Networks (BAN) which shows the key cellular pathways
inﬂuenced by MTR (Fig. S12). Thus MTR is a regulator of histone
H3K18Ac in vitro and ex vivo which could be modulating global
gene expression.
4. Discussion
Current report demonstrates the physical association of MTR
with core histone(s) in the absence of a bivalent metal ion. This
interaction occurs even at high ionic strength thereby suggesting
the speciﬁc nature of the recognition among the histone(s) and
MTR and ruling out the possibility of non-speciﬁc association of
the anionic MTR with positively charged histone(s). Till date the
transcription inhibitory potential of MTR has been ascribed to its
DNA binding ability [3,4]. Earlier reports by our group had shown
that the binding of DNA and chromatin with MTR occurs only in
the presence of bivalent metal ions like Mg2+ [20,21,25,42]. The
interaction of MTR:M2+ complexes with chromatin was proposed
to be via the minor groove of DNA with the histone proteins having
a negative impact on the binding interactions between antibi-
otic:Mg2+ complexes (complex I, 1:1 in terms of MTR:Mg2+ and
complex II 2:1 in terms of MTR:Mg2+) and DNA [42]. So, the present
report of the association of MTR with histone proteins indicates an
additional intracellular mode of action of MTR. It places MTR
among the list of DNA binding small molecules exhibiting dual
binding mode in the chromatin context [30–33]. It is noteworthy
that the association of MTR with histones does not require the
presence of bivalent metal ion like Mg2+.
Steady state ﬂuorescence spectroscopy characterizes an
association of MTR with core histone components of chromatin.
The difference in the trend of ﬂuorescence change of the chromo-
phore in MTR upon association with chromatin, individual histones
and core octamer can be ascribed to the altered electronic environ-
ment and other parameters such as the local polarity of the histone
bound MTR. Literature reports show that there is an enhancement
in the ﬂuorescence intensity when MTR binds to DNA in presence
of Mg2+ [25] whereas ﬂuorescence intensity decreases upon bind-
ing of MTR to bivalent metal ions, like Mg2+, Zn2+, etc. [20,49].
The physical environment in case of DNA, chromatin, free histones
and assembled octamer are different. Hence the peak position and
the trend in variation of emission intensity of the chromophore in
MTR differ in these scenarios.
Since we have observed that binding afﬁnity of MTR follows the
order: core histones > naked DNA > DNA/histone complex, it might
be proposed that MTR binding to DNA is partially precluded by core
histones. MTR binds to chromatin/chromatosome even in absence
of Mg2+ and the apparent dissociation constants obtained suggest
that the major mode of binding of MTR in chromatin differs in pres-
ence and absence of the bivalent metal ion Mg2+ (Table S1).
Absence of any radical change in the CD spectral shape of MTR
upon association with histones implies that the binding couldoriginate from surface complementarity followed by favorable
non-covalent interactions. It is worth-mentioning that CD
spectroscopy is a frequently used tool to examine ligand–
macromolecule interaction [42,30,50] and was employed to study
the association of daunomycin (minor groove binder) and
mitoxantrone (intercalator) with histones [51,52].
The thermodynamic scenario of MTR–histone(s) interactions
was obtained from ITC. Negative enthalpy changes might be attrib-
uted to the stacking interactions and hydrogen bonding between
the potential loci of MTR and its counterparts in histone, both
amide backbone and side chains. Additionally, electrostatic inter-
actions of the anionic MTR with positively charged side chains of
the histones possibly contribute to the favorable negative enthalpy
changes. The negative entropy values might originate from the
ordering of the water molecules at the surface of the histones
and MTR as a sequel to the association.
The dissociation constant values characterizing histone–MTR
association are not same by the two methods, ﬂuorescence and
ITC. Such disagreement of the two methodologies is not counter-
intuitive and was justiﬁed earlier in case of polymer-small ligand
association [53]. It has been attributed to higher concentration of
the polymer and ligand necessary to obtain measurable enthalpy
change.
To throw light on the speciﬁcity of MTR–core histone(s) interac-
tions, experiments were designed to check if MTR interacts with
the linker histone. Results from both steady state ﬂuorescence
spectroscopy and ITC provide direct evidence that MTR has no
binding afﬁnity towards linker histone H1. It may also be noted
that MTR does not induce gross structural alteration of chromatin
by histone H1 eviction as observed through EM and DLS measure-
ments. Thus the hierarchical level of chromatin folding is not
adversely affected in presence of MTR.
We have also examined whether MTR, like other dual binders
[30,31,46], modulate histone modiﬁcations. MTR could selectively
alter H3K18Ac but not H3K9Ac/H3K27Ac. Acetylation levels of his-
tone H4 at lysine K5 and K8 were also unaffected in presence of
MTR. These observations indicate that probably MTR has a site-
speciﬁc interaction to histone H3 tail and could be sequestering
the key residues which are modiﬁed by the HAT enzyme. Thus var-
ious sites modiﬁed by the same HAT are differentially affected by
MTR, indicating probably the mechanism is not through enzyme
active site targeting.
H3K18Ac is also altered in presence of MTR in the cellular
context. The ligand concentration chosen had no effect on cell
survivability as observed through MTT assay and ﬂow cytometry
analysis. Ability of MTR to bind DNA and core histones and selec-
tively modulate histone post-translational modiﬁcation implicates
its role in regulating global gene expression. Genome-wide pertur-
bation of gene expression upon treatment with MTR in sarcoma
cell lines (TC32 and TC71) observed from reanalysis of microarray
data reveals that apart from the genes involved in DNA binding (eg.
Zinc ﬁnger transcription factors) those involved in regulation of
chromatin function including histone modiﬁcation (Supplemen-
tary_Doc2, Table I) were differentially expressed. The alteration
of H3K18Ac upon MTR treatment in HeLa cells is possibly a basal
activity of the ligand as genes harboring H3K18Ac have been found
to be down-regulated in MTR treated other cell lines. Thus,
although speculative, the altered gene expression could be
following a similar trend in HeLa cells. Earlier studies on chromatin
binding molecules capable of altering histone modiﬁcations have
reported alteration in the gene expression upon ligand treatment
[30]. In case of SGR, there is no preference for up-regulated or
down-regulated genes. Since MTR represses the expression of
H3K18Ac, a transcription activation signature, we speculated a glo-
bal down-regulation of gene expression upon MTR treatment. In
994 A. Banerjee et al. / FEBS Open Bio 4 (2014) 987–995accordance, we indeed ﬁnd a repression of gene expression upon
MTR treatment by reanalyzing the microarray results.
In summary, we have identiﬁed the dual binding potential of
MTR in the chromatin context and have shown that MTR
modulates H3K18Ac status, an epigenetic signature of active chro-
matin. Its histone binding potential suggests an additional mode of
action of MTR. Further, its ability to affect global gene expression
indicates a complex mechanism of action of MTR in biological
context where DNA and core histones exist as competing binding
substrates. This new ﬁnding could have a broader biological impli-
cation and lends a new dimension to the role of MTR in the cellular
context.
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